Apollon Formularies plc Directors' Dealing (1849Z)

TIDMAPOL

RNS Number : 1849Z

Apollon Formularies plc

13 September 2022

13 September 2022

Apollon Formularies Plc

("Apollon" or the "Company")

Directors' Dealing

Apollon Formularies plc (AQSE: APOL), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, announces that it has been notified on 13(th) of September 2022, that Roderick ("Rod") Claude McIllree, Non-Executive Director, has transferred 10,000,000 Ordinary Shares for nil consideration to Stene Jacobs, Chief Operating Officer, on 13(th) of September 2022.

Following the transfer, Rod McIllree is interested in 207,485,940 Ordinary Shares representing approximately 26.9% of the issued share capital of the Company.

Following the transfer, Stene Jacobs is interested in 11,382,306 Ordinary Shares representing approximately 1.48% of the issued share capital of the Company.

The Directors of the Company accept responsibility for the contents of this announcement.

ENDS

For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies

   Tel:                                                      [phone] 
   Stene Jacobs                                      [e-mail] 

Peterhouse Capital Limited (Corporate Adviser)

   Tel:                                                       [phone] 
   Guy Miller                                           [e-mail] 

BlytheRay (Financial PR/IR-London)

   Tel:                                                         [phone] 
   Tim Blythe/Megan Ray                  [e-mail] 

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1.   Details of the person discharging managerial responsibilities/person closely associated 
 a)   Name:                                                          Roderick ("Rod") Claude McIllree 
 2.   Reason for the notification 
 a)   Position/status:                                               Non-Executive Director 
 b)   Initial notification/Amendment:                                Initial notification 
 3.   Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
 a)   Name:                                                          Apollon Formularies plc 
 b)   LEI:                                                           21300ZW9OCVM8OIEO02 
 4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
 a)   Description of the financial instrument, type of instrument:   Ordinary shares of no par value 
       Identification code:                                             IM00BJ0LRD77 
 b)   Nature of the transaction:                                     Transfer to another PDMR for Nil Consideration 
 c)   Price(s) and volume(s):                                         Issue of shares Price(s)    Volume(s) 
                                                                        Nil         10,000,000 
 
                                                                       Issue of warrants Price(s)   Volume(s) 
                                                                        N/A        N/A 
 d)   Aggregated information:                                        Single transaction as in 4 c) above 
       Aggregated volume:                                             Issue of shares Price(s)   Volume(s) 
       Price: 
 
                                                                      Issue of warrants Price(s)   Volume(s) 
                                                                       N/A        N/A 
 e)   Date of the transaction:                                       13 September 2022 
 f)   Place of the transaction:                                      AQSE Growth Market 
 
 
 1.   Details of the person discharging managerial responsibilities/person closely associated 
 a)   Name:                                                          Stene Jacobs 
 2.   Reason for the notification 
 a)   Position/status:                                               Chief Operating Officer 
 b)   Initial notification/Amendment:                                Initial notification 
 3.   Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
 a)   Name:                                                          Apollon Formularies plc 
 b)   LEI:                                                           21300ZW9OCVM8OIEO02 
 4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
 a)   Description of the financial instrument, type of instrument:   Ordinary shares of no par value 
       Identification code:                                             IM00BJ0LRD77 
 b)   Nature of the transaction:                                     Receipt from another PDMR for Nil Consideration 
 c)   Price(s) and volume(s):                                         Issue of shares Price(s)    Volume(s) 
                                                                        Nil         10,000,000 
 
                                                                       Issue of warrants Price(s)   Volume(s) 
                                                                        N/A        N/A 
 d)   Aggregated information:                                        Single transaction as in 4 c) above 
       Aggregated volume:                                             Issue of shares Price(s)   Volume(s) 
       Price: 
 
                                                                      Issue of warrants Price(s)   Volume(s) 
                                                                       N/A        N/A 
 e)   Date of the transaction:                                       13 September 2022 
 f)   Place of the transaction:                                      AQSE Growth Market 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEAENAFEXAEAA

(END) Dow Jones Newswires

September 13, 2022 02:02 ET (06:02 GMT)